These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2404820)

  • 21. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
    Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
    Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate.
    Kerr DE; Garrigues US; Wallace PM; Hellström KE; Hellström I; Senter PD
    Bioconjug Chem; 1993; 4(5):353-7. PubMed ID: 8274519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
    Bagshawe KD; Sharma SK; Springer CJ; Rogers GT
    Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
    Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
    Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging beyond the diagnosis: image-guided enzyme/prodrug cancer therapy.
    Tong X; Chen X; Li C
    Acta Biochim Biophys Sin (Shanghai); 2011 Jan; 43(1):4-12. PubMed ID: 21134886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific activation of prodrugs: is there a role for nuclear medicine?
    Antunes IF; Haisma HJ; de Vries EF
    Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302
    [No Abstract]   [Full Text] [Related]  

  • 33. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
    Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG
    Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
    Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
    Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
    J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.